These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15847006)

  • 21. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM
    Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue-specific regulation of 11β hydroxysteroid dehydrogenase type-1 mRNA expressions in Cushing's syndrome mouse model.
    Nishiyama M; Iwasaki Y; Nakayama S; Okazaki M; Taguchi T; Tsuda M; Makino S; Fujimoto S; Terada Y
    Steroids; 2022 Jul; 183():109021. PubMed ID: 35339573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
    Stewart PM
    Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
    Walker BR; Andrew R
    Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome.
    Joharapurkar A; Dhanesha N; Shah G; Kharul R; Jain M
    Pharmacol Rep; 2012; 64(5):1055-65. PubMed ID: 23238463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of hypertension in Cushing's syndrome: possible role of 11beta-hydroxysteroid dehydrogenase type 2 in kidneys and vascular cells.
    Miyamori I
    Intern Med; 2002 Apr; 41(4):249-50. PubMed ID: 11993781
    [No Abstract]   [Full Text] [Related]  

  • 30. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
    Seckl JR; Walker BR
    Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of 11beta-HSD1: a potential treatment for the metabolic syndrome.
    St Jean DJ; Wang M; Fotsch C
    Curr Top Med Chem; 2008; 8(17):1508-23. PubMed ID: 19075762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
    Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
    Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.
    Gathercole LL; Lavery GG; Morgan SA; Cooper MS; Sinclair AJ; Tomlinson JW; Stewart PM
    Endocr Rev; 2013 Aug; 34(4):525-55. PubMed ID: 23612224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients.
    Torrecilla E; Fernández-Vázquez G; Vicent D; Sánchez-Franco F; Barabash A; Cabrerizo L; Sánchez-Pernaute A; Torres AJ; Rubio MA
    Obes Surg; 2012 Mar; 22(3):478-86. PubMed ID: 21964795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The metabolic syndrome as intrahepatocytic Cushing's syndrome].
    Fernández Vázquez G; Torrecilla García E; Rubio Herrera MÁ
    Endocrinol Nutr; 2011 Apr; 58(4):153-6. PubMed ID: 21371955
    [No Abstract]   [Full Text] [Related]  

  • 36. Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery.
    Thomas MP; Potter BV
    Future Med Chem; 2011 Mar; 3(3):367-90. PubMed ID: 21446847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure based design of 11β-HSD1 inhibitors.
    Singh S; Tice C
    Curr Pharm Biotechnol; 2010 Nov; 11(7):779-91. PubMed ID: 20809895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.
    Baudrand R; Carvajal CA; Riquelme A; Morales M; Solis N; Pizarro M; Escalona A; Boza C; Pérez G; Domínguez A; Arrese M; Fardella CE
    Obes Surg; 2010 Jan; 20(1):77-83. PubMed ID: 19690925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism.
    Morgan SA; Hassan-Smith ZK; Doig CL; Sherlock M; Stewart PM; Lavery GG
    J Endocrinol; 2016 Jun; 229(3):277-86. PubMed ID: 27048233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased 11beta-hydroxysteroid dehydrogenase type-1 and hexose-6-phosphate dehydrogenase in liver and adipose tissue of rat offspring exposed to alcohol in utero.
    Nammi S; Dembele K; Nyomba BL
    Am J Physiol Regul Integr Comp Physiol; 2007 Mar; 292(3):R1101-9. PubMed ID: 17122334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.